Suvretta Capital Management’s Benitec Biopharma BNTC Stock Holding History

Suvretta Capital Management’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$123M	Hold	11,548,351	–	–	3.14%	7
2025 Q4	$156M	Buy	11,548,351 +1,671,845	+17%	+$23.1M	3.19%	4
2025 Q3	$139M	Hold	9,876,506	–	–	3.55%	3
2025 Q2	$116M	Hold	9,876,506	–	–	3.48%	7
2025 Q1	$128M	Buy	9,876,506 +916,497	+10%	+$11.1M	4.77%	4
2024 Q4	$113M	Buy	8,960,009 +130,956	+1%	+$1.41M	3.86%	6
2024 Q3	$81.1M	Buy	8,829,053 +7,137,763	+422%	+$63.9M	2.6%	9
2024 Q2	$11.8M	Buy	1,691,290 +1,487,070	+728%	+$11M	0.43%	47
2024 Q1	$1.07M	Hold	204,220	–	–	0.04%	86
2023 Q4	$660K	Hold	204,220	–	–	0.03%	82
2023 Q3	$617K	Buy	204,220 +158,985	+351%	+$494K	0.03%	82
2023 Q2	$3.12M	Hold	45,235	–	–	0.17%	66
2023 Q1	$161K	Hold	45,235	–	–	0.01%	94
2022 Q4	$131K	Hold	45,235	–	–	0.01%	88
2022 Q3	$286K	Hold	45,235	–	–	0.01%	71
2022 Q2	$892K	Hold	45,235	–	–	0.03%	85
2022 Q1	$1.8M	Hold	45,235	–	–	0.05%	76
2021 Q4	$2.02M	Hold	45,235	–	–	0.04%	80
2021 Q3	$2.75M	Hold	45,235	–	–	0.05%	90
2021 Q2	$3.27M	Buy	+45,235	New	+$3.54M	0.05%	99

Other funds holding BNTC

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Suvretta Capital Management's BNTC Position: Q1 2026 in Review

Suvretta Capital Management held its Benitec Biopharma (BNTC) position steady in Q1 2026 at 11,548,351 shares worth $123M. The position accounts for 3.14% of the portfolio, ranked #7.

Suvretta Capital Management first reported a position in BNTC in Q2 2021 and has held it in 20 quarters since. The position peaked at $156M in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

Suvretta Capital Management held 11,548,351 shares of Benitec Biopharma worth $123M as of Q1 2026.
Suvretta Capital Management left its Benitec Biopharma share count unchanged in Q1 2026.
Benitec Biopharma made up 3.14% of Suvretta Capital Management's portfolio in Q1 2026, its #7 holding.
Suvretta Capital Management first reported a position in Benitec Biopharma in Q2 2021 and has held it in 20 quarters since.
Suvretta Capital Management's Benitec Biopharma position peaked at $156M in Q4 2025.
88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Suvretta Capital Management's 13F filing for Q1 2026, filed 15 May 2026.